Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 2/20 | 0.61 |
| ▸ | SMPD3 | Q9NY59 | 3/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 5/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL14158423 | 0.98 | PIK3CG (0.59) | PIK3CGSMPD3AXLHTR6CDK2 | |
| SCHEMBL13772943 | 0.80 | PIK3CG (0.57) | PIK3CGSMPD3AXLHTR6CDK2 | |
| SCHEMBL21863418 | 0.80 | PIK3CG (0.57) | PIK3CGSMPD3AXLHTR6CDK2 | |
| SCHEMBL16629030 | 0.80 | PIK3CG (0.57) | PIK3CGSMPD3AXLHTR6CDK2 | |
| SCHEMBL19309158 | 0.80 | PIK3CG (0.49) | PIK3CGSMPD3AXLHTR6CDK2 | |
| SCHEMBL31725153 | 0.80 | PIK3CG (0.57) | PIK3CGSMPD3AXLHTR6CDK2 | |
| SCHEMBL15308491 | 0.80 | PIK3CG (0.49) | PIK3CGSMPD3AXLHPGDJAK2 | |
| SCHEMBL25054381 | 0.77 | PIK3CG (0.62) | PIK3CGSMPD3AXLHTR6CDK2 | |
| SCHEMBL12146434 | 0.77 | PIK3CG (0.54) | PIK3CGSMPD3AXLHTR6CDK2 | |
| SCHEMBL15306539 | 0.77 | PIK3CG (0.54) | PIK3CGSMPD3AXLHTR6CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384787-B2 | Fused heterocyclic compounds and their use as pest control agents | PI INDUSTRIES LTD (IN) | 2025-08-12 | — | — | US | disclosed |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4066834-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | Infinity Pharmaceuticals, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20220251094-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS | PI INDUSTRIES LTD. (IN) | 2022-08-11 | — | — | US | disclosed |
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020065614-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| WO-2019148132-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| US-9828377-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9775844-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| WO-2013069165-A1 | COSMETIC COMPOSITION FOR KERATIN FIBERS | L'OREAL (FR) | 2013-05-16 | — | — | WO | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8110580-B2 | Thiophene pyrazolopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2012-02-07 | — | — | US | disclosed |
| US-8030304-B2 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100222339-A1 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | ELI LILLY AND COMPANY | 2010-09-02 | — | — | US | disclosed |
| US-20100022560-A1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | CHEN ZHAOGEN | 2010-01-28 | — | — | US | disclosed |
| US-7304068-B2 | Substituted pyrazolo [1,5-A] pyrimidinyls and pharmaceutical uses therefore | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
| EP-1408040-B1 | Tricyclic fused heterocyclic compounds as CRFantagonists | EISAI CO LTD (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-1408040-A1 | Tricyclic fused heterocyclic compounds as CRFantagonists | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222339-A1 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | CRHR1, CRH, CRHR2 | PIK3CG 4193/4885SMPD3 4337/4885AXL 781/4885 |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | PIK3CG 582/4885SMPD3 69/4885AXL 3426/4885 |
| US-12384787-B2 | Fused heterocyclic compounds and their use as pest control agents | DDT, ACHE, KEAP1 | PIK3CG 2012/4885SMPD3 2111/4885AXL 1752/4885 |
| US-20100022560-A1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | CRH, CRHR1, CRHR2 | PIK3CG 2898/4885SMPD3 3495/4885AXL 1438/4885 |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GCGR | PIK3CG 2673/4885SMPD3 3439/4885AXL 689/4885 |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | PIK3CG 3355/4885SMPD3 1337/4885AXL 4333/4885 |
| US-20220251094-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS | DDT, ACHE, KEAP1 | PIK3CG 2012/4885SMPD3 2111/4885AXL 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.